Creating targeted treatments for certain types of cancer by inhibiting a specific protein.
Official title: Development of inhibitors to selectively target the CBX8 chromatin reader domain
Funded at Purdue University · NIH-11167283 · Data updated 2026-11-12
This study is working on new treatments for certain cancers by creating special medicines that target a protein called CBX8, which can help cancer grow and resist chemotherapy, with the goal of offering better options for patients facing these challenges.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Purdue University NIH-funded |
| Lab location | 1 site (West Lafayette, United States) |
| Project start | April 1, 2025 |
| Project end | March 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $429,123 |
| NIH project number | 1R01CA290858-01A1 |
| Project ID | NIH-11167283 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancers that show increased levels of the CBX8 protein, particularly those resistant to current therapies.
✕Less likely to help
Patients whose cancers do not involve the CBX8 protein or those with other unrelated conditions may not benefit from this research.
What this research studies
This research focuses on developing inhibitors that specifically target the CBX8 protein, which plays a role in cancer progression and resistance to chemotherapy. By utilizing advanced techniques, the research team aims to create more effective treatments for cancers associated with the mis-regulation of chromatin. The approach involves using DNA-encoded libraries to identify and enhance the potency of these inhibitors, potentially leading to better therapeutic options for patients with specific cancer types.
Why it matters
Potential benefit: If successful, this research could lead to new, more effective cancer treatments that specifically target the mechanisms driving cancer growth.
How similar studies have gone: Previous research has successfully targeted other CBX proteins with small molecules, indicating a promising avenue for developing effective cancer therapies.
Where this research is happening
-
Purdue University
West Lafayette, United States Active
Researchers
- Principal investigator: Dykhuizen, Emily Carla — Purdue University
- Study coordinator: Dykhuizen, Emily Carla
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.